Effects of Niacin Combination Therapy With Statin or Bile Acid Resin on Lipoproteins and Cardiovascular Disease

Fruchart, 2008, The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia, Am J Cardiol, 102, 1K, 10.1016/j.amjcard.2008.10.002 Barter, 2007, Effects of torcetrapib in patients with high risk for coronary events, N Engl J Med, 357, 2109, 10.1056/NEJMoa0706628 ACCORD Study Group, 2010, Effects of combination lipid therapy in type 2 diabetes mellitus, N Engl J Med, 362, 1563, 10.1056/NEJMoa1001282 AIM-HIGH Investigators, 2011, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy, N Engl J Med, 365, 2255, 10.1056/NEJMoa1107579 Schwartz, 2012, Effects of dalcetrapib in patients with a recent acute coronary syndrome, N Engl J Med, 367, 2089, 10.1056/NEJMoa1206797 HPS2-THRIVE Collaborative Group, 2013, HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment, Eur Heart J, 34, 1279, 10.1093/eurheartj/eht055 Briel, 2009, Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis, BMJ, 338, b92, 10.1136/bmj.b92 Jun, 2010, Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis, Lancet, 375, 1875, 10.1016/S0140-6736(10)60656-3 Zambon, 1999, Evidence for a new pathophysiological mechanism for coronary artery disease regression hepatic lipase–mediated changes in LDL density, Circulation, 99, 1959, 10.1161/01.CIR.99.15.1959 Canner, 1986, Fifteen year mortality in coronary drug project patients; long term benefit with niacin, J Am Coll Cardiol, 8, 1245, 10.1016/S0735-1097(86)80293-5 Brown, 1990, Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B, N Engl J Med, 323, 1289, 10.1056/NEJM199011083231901 Brown, 2001, Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease, N Engl J Med, 345, 1583, 10.1056/NEJMoa011090 Capell, 1996, Compositional differences of LDL particles in normal subjects with LDL subclass phenotype A and LDL subclass phenotype B, Arterioscler Thromb Vasc Biol, 16, 1040, 10.1161/01.ATV.16.8.1040 Goldberg, 2013, Lifestyle and metformin treatment favourably influence lipoprotein subfraction distribution in the diabetes prevention program, J Clin Endocrinol Metab, 98, 3989, 10.1210/jc.2013-1452 Gordon, 1989, High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies, Circulation, 79, 8, 10.1161/01.CIR.79.1.8 Wilson, 1988, High density lipoprotein cholesterol and mortality. The Framingham Heart Study, Arteriosclerosis, 8, 737, 10.1161/01.ATV.8.6.737 Rubins, 1995, Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention trial study group, Am J Cardiol, 75, 1196, 10.1016/S0002-9149(99)80761-9 Robins, 2001, Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial, JAMA, 285, 1585, 10.1001/jama.285.12.1585 de la Llera-Moya, 2010, The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages, Arterioscler Thromb Vasc Biol, 30, 796, 10.1161/ATVBAHA.109.199158 Khera, 2011, Cholesterol efflux capacity and atherosclerosis, N Eng J Med, 364, 127, 10.1056/NEJMoa1001689 Austin, 1988, Low-density lipoprotein subclass patterns and risk of myocardial infarction, JAMA, 260, 1917, 10.1001/jama.1988.03410130125037 Musunuru, 2009, Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk, Arterioscler Thromb Vasc Biol, 29, 1975, 10.1161/ATVBAHA.109.190405 St-Pierre, 2005, Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Québec cardiovascular study, Arterioscler Thromb Vasc Biol, 25, 553, 10.1161/01.ATV.0000154144.73236.f4 Tsai, 2014, New automated assay of small dense low-density lipoprotein cholesterol identifies risk of coronary heart disease. The multi-ethnic study of atherosclerosis, Arterioscler Thromb Vasc Biol, 34, 196, 10.1161/ATVBAHA.113.302401 Ayyobi, 2003, Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia, Arterioscler Thromb Vasc Biol, 23, 1289, 10.1161/01.ATV.0000077220.44620.9B Zambon, 2006, Genetically determined apo B levels and peak LDL density predict angiographic response to intensive lipid-lowering therapy, J Intern Med, 259, 401, 10.1111/j.1365-2796.2006.01626.x Williams, 2013, Levels of cholesterol in small LDL particles predict atherosclerosis progression and incident CHD in the HDL-atherosclerosis treatment study (HATS), PloS One, 8, e56782, 10.1371/journal.pone.0056782 Guyton, 2013, Relationship of lipoproteins to cardiovascular events: the aim-high trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High triglycerides and Impact on Global Health outcomes), J Am Coll Cardiol, 62, 1580, 10.1016/j.jacc.2013.07.023 Albers, 2013, Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglyceride and Impact on Global Health Outcomes), J Am Coll Cardiol, 62, 1575, 10.1016/j.jacc.2013.06.051 Berglund, 2012, Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab, 97, 2969, 10.1210/jc.2011-3213